Market Outline: Global Autologous Matrix-induced Chondrogenesis Market
Autologous matrix-induced chondrogenesis is single step cartilage restoration process that helps to repair the articular cartilage damage. In this process, the micro fracture is combines with the bi-layer collagen I/III. Membrane. AMIC is developed for the treatment of osteochondral and traumatic chondral lesions to establish the first line treatment. The AMIC slows down the cartilage degeneration to delay or avoid the partial or total joint replacement surgery.
Market Dynamics: Global Autologous Matrix-induced Chondrogenesis Market
Increase in the geriatric population more prone for bone and joint disorders is a key factor drives the global autologous matrix-induced chondrogenesis market. Moreover, rise in number of sports injuries, increase in the preference for minimally invasive surgical procedures, less post-operative complications and lower cost compared with conventional surgeries, increasing in the R&D for the advancement in AMIC, rise in disposable income, and increase in the awareness about AMIC in developed and emerging countries are anticipated to surge the global autologous matrix-induced chondrogenesis market over the forecast years. However, lack of favorable reimbursement policies and dearth of skilled professionals and clinical date are restrain the growth of autologous matrix-induced chondrogenesis market over the forecast timeframe.
Global autologous matrix-induced chondrogenesis market was valued at US $ XX Mn and expected to grow at XX% Compound Annual Growth Rate (CAGR) from 2018 to 2024.
Market Scope: Global Autologous Matrix-induced Chondrogenesis Market
Global autologous matrix-induced chondrogenesis market is segmented based on product type, material type, and end user
Based on material type, market is segmented into the following:
- Hyaluronic Acid
- Polyethylene glycol (PEG)
- Polylactic-co-glycolic Acid
Based on the application, market is segmented into the following:
- Knee Cartilage Repair
- Elbow Cartilage Repair
- Hip Cartilage Repair
Based on the end users, the market is segmented into the following:
- Ambulatory Surgical Centers (ASCs)
Geographically, global autologous matrix-induced chondrogenesis market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. North America autologous matrix-induced chondrogenesis market is poised to grow due to rise in prevalence of bone and joint disorders, increase in R&D activities by market players, and sophisticated healthcare infrastructure are bolster the market. Europe autologous matrix-induced chondrogenesis market is driving by rise in demand for minimally invasive surgical procedures, presence of skilled professionals in developed countries, and increase in number of sports injuries are surge the market. Asia Pacific autologous matrix-induced chondrogenesis market has prominent share attributed to increase in the medical tourism in Asia Pacific countries, rise in disposable income, and large patient pool in Asia Pacific region are fuel the market.
- Anika Therapeutics, Inc. (U.S.)
- Arthro-Kinetics AG (Germany)
- Braun Melsungen AG (Germany)
- BioTissue AG (Switzerland)
- CartiHeal (Israel)
- Geistlich Pharma AG (Switzerland)
- JRI Orthopaedics Ltd. (AK Medical) (U.K.)
- Matricel GmbH Germany)
- Smith & Nephew plc (U.K.)
- Zimmer Biomet Holdings (U.S.)